PF-04217903 is primarily utilized in the field of medical research, particularly in the study of cancer therapies. It functions as a selective inhibitor of the c-Met receptor tyrosine kinase, which plays a significant role in tumor growth and metastasis. By targeting this receptor, PF-04217903 helps researchers understand the mechanisms of cancer progression and evaluate potential therapeutic strategies. Its application is crucial in preclinical studies to assess the efficacy of inhibiting c-Met in various cancer models, providing insights that could lead to the development of targeted cancer treatments.